You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb1921729 |
---|---|
Category | Proteins |
Description | As the most abundant envelop glycoprotein of EBV, gp350 is encoded by the BLLF1 gene, heavily glycosylated and localizing to a variety of subcellular compartments of replicating cells. BLLF1 gp350 comprises an external, transmembrane, and internal domain. The interaction between EBV and the B lymphocyte surface is initially mediated by gp350 through binding to a B-cell surface receptor, CD21. The gp350 N-terminal region contains the B-cell binding domain, which can be recognized by EBV-neutralizing monoclonal antibody 72A1 to inhibits EBV binding and invasion of host cells. The N-terminal 9-amino-acid sequence of gp350, 21EDPGFFNVE29, which has significant homology to an 11-amino-acid sequence of C3dg, EDPGKQLYNVE, binds to purified CR2 and CR2 (+), but not to CR2 (-), B- and T-lymphoblastoid cell lines . Because of its essential properties, gp350 has been considered as a potential candidate for an EBV vaccine. |
Tested applications | CLIA, IA, LF |
Form/Appearance | Purified,Liquid |
Purity | > 90% pure (SDS-PAGE). |
MW | 52.25 kDa |
Source | HEK293 |
Storage | For long term storage, the product should be stored at -20°C or lower. |
Note | For research use only |
Sample Types | Test sample type: Whole Blood. Test sample source: Human |
Expiration Date | 6 months from date of receipt. |
CLIA, IA, LF | |
> 90% pure (SDS-PAGE). | |
89.13 kDa | |
HEK293 |